Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States
The Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States is a deleted U.S. Department of Health and Human Services (HHS) publication, preserved here in its unchanged original form. Developed by the Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission, this document provides evidence-based guidelines for healthcare providers on the use of antiretroviral therapy (ART) during pregnancy and strategies to reduce the risk of perinatal HIV transmission.
Key Features of the Guidelines:
HIV Testing & Identification of Perinatal HIV Exposure: Recommendations on prenatal and postpartum HIV testing, including strategies to identify and manage perinatal and postnatal HIV exposure.
Pre-Exposure Prophylaxis (PrEP) for HIV Prevention: Guidance on the use of PrEP before conception, during pregnancy, and postpartum to prevent maternal HIV acquisition.
ART Recommendations for Pregnant Individuals:
Guidelines for initiating or continuing ART during pregnancy.
Preferred and alternative ART regimens for antiretroviral-naïve individuals.
Considerations for pregnant individuals already on ART at the time of conception.
Intrapartum HIV Management: Strategies for reducing perinatal transmission during labor and delivery, including cesarean section recommendations based on viral load.
Infant Care & Antiretroviral Management:
Antiretroviral prophylaxis for newborns based on maternal viral suppression.
Infant HIV testing schedules and postnatal management.
Breastfeeding recommendations for individuals with HIV, balancing maternal viral suppression with transmission risks.
Special Populations Considerations:
HIV prevention and treatment strategies for transgender and gender-diverse individuals who are pregnant.
Management of HIV and co-infections, including hepatitis B, hepatitis C, and HIV-2.
Guidelines for individuals with perinatally acquired HIV who become pregnant.
Disclosure:
This document is presented in its unaltered form as originally published by the HHS before its removal.
The Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States is a deleted U.S. Department of Health and Human Services (HHS) publication, preserved here in its unchanged original form. Developed by the Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission, this document provides evidence-based guidelines for healthcare providers on the use of antiretroviral therapy (ART) during pregnancy and strategies to reduce the risk of perinatal HIV transmission.
Key Features of the Guidelines:
HIV Testing & Identification of Perinatal HIV Exposure: Recommendations on prenatal and postpartum HIV testing, including strategies to identify and manage perinatal and postnatal HIV exposure.
Pre-Exposure Prophylaxis (PrEP) for HIV Prevention: Guidance on the use of PrEP before conception, during pregnancy, and postpartum to prevent maternal HIV acquisition.
ART Recommendations for Pregnant Individuals:
Guidelines for initiating or continuing ART during pregnancy.
Preferred and alternative ART regimens for antiretroviral-naïve individuals.
Considerations for pregnant individuals already on ART at the time of conception.
Intrapartum HIV Management: Strategies for reducing perinatal transmission during labor and delivery, including cesarean section recommendations based on viral load.
Infant Care & Antiretroviral Management:
Antiretroviral prophylaxis for newborns based on maternal viral suppression.
Infant HIV testing schedules and postnatal management.
Breastfeeding recommendations for individuals with HIV, balancing maternal viral suppression with transmission risks.
Special Populations Considerations:
HIV prevention and treatment strategies for transgender and gender-diverse individuals who are pregnant.
Management of HIV and co-infections, including hepatitis B, hepatitis C, and HIV-2.
Guidelines for individuals with perinatally acquired HIV who become pregnant.
Disclosure:
This document is presented in its unaltered form as originally published by the HHS before its removal.
The Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States is a deleted U.S. Department of Health and Human Services (HHS) publication, preserved here in its unchanged original form. Developed by the Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission, this document provides evidence-based guidelines for healthcare providers on the use of antiretroviral therapy (ART) during pregnancy and strategies to reduce the risk of perinatal HIV transmission.
Key Features of the Guidelines:
HIV Testing & Identification of Perinatal HIV Exposure: Recommendations on prenatal and postpartum HIV testing, including strategies to identify and manage perinatal and postnatal HIV exposure.
Pre-Exposure Prophylaxis (PrEP) for HIV Prevention: Guidance on the use of PrEP before conception, during pregnancy, and postpartum to prevent maternal HIV acquisition.
ART Recommendations for Pregnant Individuals:
Guidelines for initiating or continuing ART during pregnancy.
Preferred and alternative ART regimens for antiretroviral-naïve individuals.
Considerations for pregnant individuals already on ART at the time of conception.
Intrapartum HIV Management: Strategies for reducing perinatal transmission during labor and delivery, including cesarean section recommendations based on viral load.
Infant Care & Antiretroviral Management:
Antiretroviral prophylaxis for newborns based on maternal viral suppression.
Infant HIV testing schedules and postnatal management.
Breastfeeding recommendations for individuals with HIV, balancing maternal viral suppression with transmission risks.
Special Populations Considerations:
HIV prevention and treatment strategies for transgender and gender-diverse individuals who are pregnant.
Management of HIV and co-infections, including hepatitis B, hepatitis C, and HIV-2.
Guidelines for individuals with perinatally acquired HIV who become pregnant.
Disclosure:
This document is presented in its unaltered form as originally published by the HHS before its removal.